Please Wait.....
Report
Canada Ophthalmology Drugs & Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-08-01 I 70 Pages I Mordor Intelligence
Canada Ophthalmology Drugs & Devices Market Analysis
The Canada ophthalmology drugs & devices market size reached USD 2.65 billion in 2025 and is forecast to climb to USD 3.33 billion by 2030, advancing at a 5.95% CAGR. Rising provincial reimbursement for advanced imaging and the arrival of lower-priced biosimilar anti-VEGF agents are expanding patient access, while hospital and ambulatory sites adopt lean surgical models that cut episode-of-care costs. Suppliers of portable diagnostics are finding new demand in remote and Indigenous communities, and multinational manufacturers are reinforcing their pipelines through targeted acquisitions that accelerate entry into cell and gene therapies. At the same time, procurement rules that favor sustainable supply chains are nudging device makers to localize assembly and documentation.
Canada Ophthalmology Drugs & Devices Market Trends and Insights
Provincial Adoption of Advanced Imaging Reimbursement Codes in Ontario & British Columbia
The March 2025 update to Ontario's Schedule of Benefits raised reimbursements for optical coherence tomography and fundus photography by 12%, spurring clinics to invest in next-generation scanners. Early data show a 23% jump in glaucoma and diabetic-retinopathy detection, and vendors of handheld OCT units report double-digit order growth as community optometrists qualify for the new fees. British Columbia's Medical Services Plan created tiered fees that reward community-based screening, shifting volumes from tertiary hospitals to smaller practices and broadening the installed base for imaging hardware.
Accelerated Health Canada Approvals for Biosimilar Anti-VEGF Agents
Ranibizumab biosimilar FYB201 entered the Canadian formulary in late 2023, and aflibercept follow-on Yesafili is cleared for July 2025 launch. Ten provinces have adopted mandatory biosimilar switching in public drug plans, triggering a 15-20% price drop for retinal injections. Surveys by the Canadian Ophthalmology Society show 80% of specialists accept biosimilars as a route to wider access while seeking to retain prescribing freedom.
Provincial Cost Caps on Premium Intraocular Lenses Curtailing Adoption
Ontario's Health Insurance Plan reimburses only monofocal lenses, leaving patients to self-pay the full upgrade cost for toric or multifocal optics. A 2024 population-based study found surgery volumes rose for residents in the wealthiest quintile but fell for the lowest, underscoring a two-tier pattern in access. Manufacturers now tailor go-to-market models toward high-volume private clinics that can navigate mixed-billing rules.
Other drivers and restraints analyzed in the detailed report include:
Indigenous Vision-Screening Programs Driving Portable Diagnostics Uptake in Northern Canada / Rising Childhood Myopia Rates Fueling Demand for Refractive Management Solutions / Shortage of Ophthalmic Surgeons in Atlantic Canada Limiting Procedure Volume /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Devices generated USD 1.55 billion in revenue and represented 62.11% of the Canada ophthalmology drugs & devices market in 2024. Surgical platforms for cataract extraction still dominate device value, leveraging public-private centers in New Brunswick that target thousands of extra cases annually. Diagnostic and monitoring equipment is the fastest-advancing slice, logging an 8.06% CAGR as reimbursement for OCT and ultra-widefield fundus imaging broadens. Ontario's 12% fee bump for retinal scans, for instance, has already spurred community optometrists to order compact OCT units, extending reach beyond tertiary hospitals. Device makers are also integrating tele-ophthalmology modules so northern clinics can transmit images for remote grading, meeting demand triggered by Indigenous vision programs.
Drugs delivered USD 950 million in 2024 sales. Anti-VEGF agents for retinal disease are the growth locomotive as biosimilars compress prices and provincial formularies embrace mandatory switching. Health Canada's green light for ranibizumab FYB201 and pending approval of aflibercept Yesafili lower payer outlays and create headroom to treat more patients. Glaucoma drug volumes hold steady, yet surgeons increasingly pair medication with minimally invasive implantable devices such as the Hydrus Microstent, which a 2025 Canadian cost study showed produced 9.351 QALYs at CAD 26,770-less than cataract surgery alone.
Cataract captured 31.11% of 2024 spending, reflecting its status as the most common ocular surgery and the backbone of surgical-device revenue. Manitoba's wait-time dashboard listed more than 3,100 patients queued for cataract operations, with median waits of 6-9 weeks-a level that continues to fuel throughput investments. Innovation focuses on premium intraocular lenses and femtosecond laser platforms, although cost caps in large provinces temper premium adoption rates.
Diabetic retinopathy is projected to grow at a 7.24% CAGR, powered by national diabetes incidence and earlier screening. Consensus guidelines released in 2024 highlight personalized injection intervals and systemic-risk management, spurring demand for imaging and anti-VEGF therapy. Glaucoma remains substantial as novel shunts such as XEN Gel and PreserFlo Microshunt reshape management for moderate disease. Age-related macular degeneration markets gain from the approval of avacincaptad pegol for geographic atrophy, while regulatory reviews for dual-pathway antibodies such as faricimab enlarge future options.
The Canada Ophthalmology Drugs & Devices Market Report is Segmented by Product (Devices and Drugs), Drug Class (Glaucoma Drugs, and More), Disease Indication (Cataract, and More), End-User (Hospital, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Alcon / Bausch Health / Johnson & Johnson Vision Care / Carl Zeiss / Novartis / Topcon / Glaukos / Lumenis / HOYA / STAAR Surgical / Heidelberg Engineering / Nidek / CooperVision Inc. /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Provincial Adoption of Advanced Imaging Reimbursement Codes in Ontario & British Columbia
4.2.2 Accelerated Health Canada Approvals for Biosimilar Anti-VEGF Agents
4.2.3 Indigenous Vision-Screening Programs Driving Portable Diagnostics Uptake in Northern Canada
4.2.4 National Pharmacare Negotiations Encouraging Pipeline Investment in Rare Ocular Disease Gene Therapies
4.2.5 Rising Childhood Myopia Rates Fueling Demand for Refractive Management Solutions
4.2.6 Post-Pandemic Cataract Surgery Backlog Boosting Surgical Device Utilization
4.3 Market Restraints
4.3.1 Provincial Cost Caps on Premium Intraocular Lenses Curtailing Adoption
4.3.2 Cross-Border Supply-Chain Vulnerabilities Causing Device Stock-Outs
4.3.3 Shortage of Ophthalmic Surgeons in Atlantic Canada Limiting Procedure Volume
4.3.4 Hospital Sustainability Procurement Rules Raising Import Compliance Costs
4.4 Regulatory Outlook
4.5 Porter's Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers / Consumers
4.5.3 Bargaining Power of Suppliers
4.5.4 Threat of Substitute Products
4.5.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Product
5.1.1 Devices
5.1.1.1 Diagnostic & Monitoring Devices
5.1.1.1.1 OCT Scanners
5.1.1.1.2 Fundus & Retinal Cameras
5.1.1.1.3 Autorefractors & Keratometers
5.1.1.1.4 Corneal Topography Systems
5.1.1.1.5 Ultrasound Imaging Systems
5.1.1.1.6 Perimeters & Tonometers
5.1.1.1.7 Other Diagnostic & Monitoring Devices
5.1.1.2 Surgical Devices
5.1.1.2.1 Cataract Surgical Devices
5.1.1.2.2 Vitreoretinal Surgical Devices
5.1.1.2.3 Refreactive Surgical Devices
5.1.1.2.4 Glaucoma Surgical Devices
5.1.1.2.5 Other Surgical Devices
5.1.1.3 Vision Care Devices
5.1.1.3.1 Spectacles Frames & Lenses
5.1.1.3.2 Contact Lenses
5.1.2 Drugs
5.1.2.1 Glaucoma Therapeutics
5.1.2.2 Retinal Disorder Therapeutics (Anti-VEGF & Others)
5.1.2.3 Dry Eye Therapeutics
5.1.2.4 Allergic Conjunctivitis & Inflammatory Therapeutics
5.1.2.5 Other Ophthalmic Drugs
5.2 By Drug Class
5.2.1 Glaucoma Drugs
5.2.2 Retinal Disorder Drugs
5.2.3 Dry Eye Drugs
5.2.4 Allergic Conjunctivitis and Inflammation Drugs
5.2.5 Other Drug Classes
5.3 By Disease Indication
5.3.1 Cataract
5.3.2 Glaucoma
5.3.3 Diabetic Retinopathy
5.3.4 Other Disease Indications
5.4 By End-user
5.4.1 Hospitals
5.4.2 Specialty Ophthalmic Clinics
5.4.3 Ambulatory Surgery Centers (ASCs)
5.4.4 Other End-users
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
6.3.1 Alcon Inc.
6.3.2 Bausch Health Companies Inc.
6.3.3 Johnson & Johnson Vision Care
6.3.4 Carl Zeiss Meditec AG
6.3.5 Novartis AG
6.3.6 Topcon Corporation
6.3.7 Glaukos Corporation
6.3.8 Lumenis Be Ltd.
6.3.9 HOYA Corporation
6.3.10 STAAR Surgical
6.3.11 Heidelberg Engineering GmbH
6.3.12 Nidek Co. Ltd.
6.3.13 CooperVision Inc.
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security